Coverage from the 62nd ASH Annual Meeting & Exposition
Focus on Multiple Myeloma
The 62nd ASH Annual Meeting and Exposition—originally to be held in San Diego—will be held virtually this year from December 5-8, 2020. Attendees will have access to thousands of scientific abstracts highlighting cutting-edge research in hematology in a state-of-the-art virtual exhibit hall. This conference is an opportunity to enhance your practice through educational programs while exploring new research presented by hematologists around the world. Check out highlights from the upcoming conferences to help you make the most of your time at ASH.
Study Offers New Hope for Treating Advanced Multiple Myeloma
Patients diagnosed with advanced or relapsed multiple myeloma find themselves with few treatment options. They’re often resistant to many of the best available therapies, leaving them with a short lifespan after diagnosis. Soon, that may be changing.
Novel Drug Triggers Significant Response in R/R Multiple Myeloma
Although outcomes have improved for patients with multiple myeloma (MM) in recent years with available treatments, novel drugs are needed to address the unmet needs of those with disease refractory to all available therapies.
Comparison of Therapy Outcomes in Multiple Myeloma Patients in US & Canada
Multiple myeloma (MM) patients treated with bortezomib and lenalidomide had better overall and long-term survival in Alberta, Canada, compared to patients in the United States due to utilization and therapy differences. This is according to results from a new cross-country study presented at the ASH 2020 Annual Meeting (Abstract 2516).
Evaluation of Tumor Mutational Burden in Multiple Myeloma Cells
Melphalan is a nitrogen mustard alkylating agent used to treat patients with multiple myeloma. In the Phase III IFM/DFCI2009 study (NCT01191060), the combination of lenalidomide, bortezomib, and dexamethasone (RVD arm) was evaluated alone or in combination with high-dose melphalan plus autologous stem cell transplantation (ASCT) (HDM arm) (N Engl J Med 2017;376:1311-1320).
Projecting the Incidence & Prevalence of Multiple Myeloma in the U.S.
The incidence and prevalence by line of therapy for multiple myeloma patients is projected to increase in the U.S. between 2020 and 2025, according to a recent analysis. These findings were presented during the 2020 ASH Annual Meeting and Exposition (Abstract 2300).
Triplet Combo With Subcutaneous Daratumumab Prolongs PFS in R/R Multiple Myeloma
A combination of daratumumab subcutaneous plus pomalidomide and dexamethasone (D-Pd) is an effective and convenient treatment for patients with relapsed/refractory multiple myeloma (MM) who had received 1 or more lines of prior therapy, including lenalidomide and a proteasome inhibitor.